{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-002698","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.025516+00:00","generated_at":"2026-06-19T13:34:09.228443+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acasti Pharma Q3 net loss $3.9M; cash $31.3M; pipeline advances to Phase 3","bullets":["Net loss $3.9M ($0.09 loss per share) vs $3.8M loss a year ago.","Cash, equivalents and ST investments $31.3M as of Dec 31, 2022; funds operations into Q2 2024.","GTX-104: Expects FDA Type C meeting in Q1 2023; may initiate Phase 3 safety study.","GTX-102 PK bridging study met all primary endpoints; Phase 3 planning underway.","GTX-101 PK study met all primary endpoints; multiple ascending dose study planned in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-002698","json":"https://secwatch.observer/filing/0000950170-23-002698.json","markdown":"https://secwatch.observer/filing/0000950170-23-002698.md","text":"https://secwatch.observer/filing/0000950170-23-002698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023002698/0000950170-23-002698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023002698/acst-20230214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T13:34:09.228443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2c8bf8dafe50b315d42ed1f78e2bd091952e89ef","claim":"Grace Therapeutics, Inc. reported financial results for the third quarter ended December 31, 2022.","evidence_excerpt":"On February 14, 2023, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023002698/0000950170-23-002698-index.htm","confidence":0.6,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}